<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Johnson & Johnson | Company News & Executive Profiles - JNJ | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/johnson+%26+johnson.html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Johnson & Johnson]]></description>
	<s:counts start="0" returned="10" found="1606" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Can Talcum Powder Give You Cancer? J&J Is About to Find Out]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005813/can-talcum-powder-give-you-cancer-jj-is-about-to-find-out/]]></link>
		<description><![CDATA[Of all the products Johnson & Johnson JNJ makes, you'd think its famous talcum Baby Powder would be free from litigation. But no. A Sioux Falls, S.D., woman claims that J&J's talc caused her ovarian cancer. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 16 Dec 2009 03:14:54 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[High Hopes Remain for Celgene's Revlimid]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F177376-high-hopes-remain-for-celgene-s-revlimid%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Hotly anticipated data from a big trial of Celgene&#8217;s CELG Revlimid in multiple myeloma were released at the American Society of Hematology Ash yesterday and, as is often the case, prompted more questions that answers. This is partly because the study, called MM-015, has not finished yet,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 09 Dec 2009 09:08:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">CELG,JNJ</category>
	</item>
	<item>
		<title><![CDATA[Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005680/shires-daytrana-patch-recall-is-8th-so-far-time-to-pull-the-plug/]]></link>
		<description><![CDATA[Shire SHPGY has voluntarily recalled the Daytrana ADHD patch citing problems with patients removing the liner on the back. It is not a safety issue, the company says. Daytrana is for children with ADHD; it is the only patch product to treat the condition. "Sudden death" is one of the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 07 Dec 2009 08:02:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/recall.html"><![CDATA[Recall]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/patch+management.html"><![CDATA[Patch Management]]></category>
		<category domain="http://resources.bnet.com/topic/shire.html"><![CDATA[Shire]]></category>
		<category domain="http://resources.bnet.com/topic/daytrana+adhd.html"><![CDATA[Daytrana ADHD]]></category>
		<category domain="http://resources.bnet.com/topic/noven.html"><![CDATA[Noven]]></category>
		<category domain="http://resources.bnet.com/topic/wilco.html"><![CDATA[Wilco]]></category>
		<category domain="http://resources.bnet.com/topic/patches.html"><![CDATA[Patches]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Shops Chase Tylenol, Motrin]]></title>
		<link><![CDATA[http://industry.bnet.com/advertising/news-analysis/shops-chase-tylenol-motrin/22786/]]></link>
		<description><![CDATA[Johnson & Johnson today confirmed that the company is reviewing creative and media planning chores on both its Tylenol and Motrin brands.Along with Interpublic Group's Deutsch, the incumbent on both assignments, sources identified these contenders: Omnicom Group units DDB in New York, Goodby, Silverstein & Partners, San Francisco and TBWA\Chiat\Day;...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 04 Dec 2009 11:50:11 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/media.html"><![CDATA[media]]></category>
		<category domain="http://resources.bnet.com/topic/brand.html"><![CDATA[Brand]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/chore.html"><![CDATA[Chore]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Fed Probe Into Johnson & Johnson Reaches Zero Hour]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/fed-probe-johnson-johnson-reaches/22604/]]></link>
		<description><![CDATA[Will federal prosecutors indict the health care giant for off-label marketing of its Natrecor heart drug? Lawyers for J&J are scheduled to meet next week with Assistant Attorney General Tony West and other Justice Department attorneys in Washington, D.C., for some serious haggling, Law.com reports, adding that a handful of...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 03 Dec 2009 06:51:01 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/u.s.+department+of+justice.html"><![CDATA[U.S. Department Of Justice]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[UK Charges Former J&J Exec With Corruption]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/uk-charges-exec-corruption/22322/]]></link>
		<description><![CDATA[Robert John Dougall, 44, a former vice president for market development at J&J's DePuy unit, was charged in connection with payments made or inducements given to medical professionals working in the Greek public health care system between 2002 and 2005, according to the UK Serious Fraud Office. The investigation remains...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 01 Dec 2009 12:47:56 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/payment.html"><![CDATA[Payment]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Celgene: New Studies Expected to Boost Sales]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175823-celgene-new-studies-expected-to-boost-sales%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  More details are being made available about studies of Celgene&#8217;s CELG blockbuster drug Revlimid.  According to Bloomberg, the results of several studies, to be released at the American Society of Hermatology meeting later this week, should lead to more widespread use of the cancer drug...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 30 Nov 2009 02:35:36 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">CELG,JNJ</category>
	</item>
	<item>
		<title><![CDATA[J&J CEO Rubs Pfizer's Face in Disastrous Consumer Products Sale of '06]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005497/jj-ceo-rubs-pfizers-face-in-disastrous-consumer-products-sale-of-06/]]></link>
		<description><![CDATA[Toldya: One year ago, BNET noted that Pfizer PFE must have been crazy to sell its consumer products unit to Johnson & Johnson JNJ. The deal included brands such as Nicorette, Zantac and Benadryl. J&J's Q3 earnings report showed that the consumer products unit has done much better than its...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 25 Nov 2009 08:11:04 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">JNJ,PFE</category>
	</item>
	<item>
		<title><![CDATA[Why J&J's Stelara Launch Should Target Dermatologists First]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005423/why-jjs-stelara-launch-should-target-dermatologists-first/]]></link>
		<description><![CDATA[Johnson & Johnson recently launched Stelara for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis. Although Stelara is entering a crowded treatment room for psoriasis, this first-in-class interleukin IL inhibitor could still put the "no more tears" back in J&J's future -- if...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 20 Nov 2009 11:48:31 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[J&J vs. 10-Year T-Bonds: The Power of Rising Dividends]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174227-j-j-vs-10-year-t-bonds-the-power-of-rising-dividends%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Rising Dividend Investing submits:  I have written and spoken about the Hidden Power of Rising Dividends compared to bonds for nearly 20 years. Yet, I find that many people do not grasp and retain the concept. The primary reason for this is that most people think of stocks as...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 19 Nov 2009 02:32:20 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/rising+dividend+investing.html"><![CDATA[Rising Dividend Investing]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
</channel>
</rss>
